Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 9/20 | 0.63 |
| ▸ | PGR | P06401 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.57 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.56 |
| ▸ | PLAT | P00750 | 2/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8281111 | 0.91 | PLAU (0.65) | PLAUPGRLMNAMAPTTDP1 | |
| SCHEMBL4880948 | 0.87 | LMNA (0.58) | PLAULMNAMAPTTDP1ALDH1A1 | |
| SCHEMBL8280451 | 0.86 | MAPT (0.55) | PLAUPGRLMNAMAPTTDP1 | |
| SCHEMBL8281101 | 0.85 | PLAU (0.66) | PLAUPGRLMNAMAPTALDH1A1 | |
| SCHEMBL4877336 | 0.85 | TDP1 (0.62) | PLAUPGRLMNAMAPTTDP1 | |
| SCHEMBL14018731 | 0.85 | MAPT (0.74) | PLAUPGRLMNAMAPTTDP1 | |
| SCHEMBL8279533 | 0.85 | TDP1 (0.62) | PLAUPGRLMNAMAPTTDP1 | |
| SCHEMBL8280443 | 0.84 | LMNA (0.55) | PLAULMNAMAPTTDP1ALDH1A1 | |
| SCHEMBL8280249 | 0.83 | LMNA (0.60) | PLAUPGRLMNAMAPTTDP1 | |
| SCHEMBL8752441 | 0.83 | ALDH1A1 (0.72) | PGRLMNAMAPTTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| WO-2005090298-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | NR1I2, ITGA2, ITGB2 | PLAU 2220/4885PGR 421/4885LMNA 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.